Location: Berlin, Germany
Start Date: Sep 09, 2026
End Date: Sep 11, 2026
Type of Event: Scientific Conferences
Attendees:

Join us in-person in Berlin, Germany for the 14th GSCN Conference, which we are supporting as a Bronze Sponsor. Learn more about our involvement in the event below (further details TBA).

Evotec at 14th GSCN Conference 2026

Oral Presentations

Off-The-Shelf Immune-Shielded iPSC-Derived CAR γδ T Cells as Novel Cell Therapy to Treat Hepatocellular Carcinoma  

Presenter: Stephanie Sontag, Senior Research Scientist, iPSC Cell Therapy
Date and Time: Thursday, 10 September, 2026, 10:00 AM- 10:15 AM

Integrating Patient Data and hiPSC Microglia to Model Alzheimer’s Disease for Drug Discovery

Presenter: Henrik Renner, Senior Research Scientist, iPSC Drug Discovery
Date and Time: Thursday, 10 September, 2026, 11:50 AM - 12:05 PM

Human iPSC Models for Safer Drug Discovery Through Predictive Teratogenicity Assessment

Presenter: Bastian Zimmer, VP iPSC Drug Discovery, Innovation
Date and Time: Friday, 11 September, 2026, 09:45 AM - 10:00 AM

Poster Presentations

Off-The-Shelf Immune-Shielded iPSC-Derived Car γδ T Cells as Novel Cell Therapy to Treat Hepatocellular Carcinoma

Presenter: Judith Hartmann, Senior Research Assistant, iPSC Cell Therapy
Date and Time: TBD

Scalable 3D Closed Stirred-Tank Reactor Enabling Multi-Lineage Differentiation for Cell Therapy

Presenter: Thomas Aleyt, Senior Research Assistant Cell Therapy, iPSC Cell Therapy
Date and Time: TBD

GMP iPSC Derived CAR Macrophages with Immune Shielding for Off the Shelf Treatment of Fibrosis

Presenter: Elisabeth Derksen, Research Assistant, iPSC Cell Therapy
Date and Time: TBD

Modeling Human Heart Atlas-Derived Disease Mechanisms in iPSC-Based Cardiac Systems

Presenter: Kinga Wrona, Research Associate, Prot Dev Core
Date and Time: TBD

E.iPSC Drug Discovery Platform Lab Equipment

iPSC Drug Discovery

The industry-leading human iPSC-based drug screening platform which can model diseases in more than 15 cell types. Patient-derived cell-based assays and an enhanced molecular understanding of disease phenotypes are crucial to improving the accuracy of this disease modelling

Learn more
Two scientists working on induced pluripotent stem cell therapy research

Co-develop iPSC-based Cell Therapies: Our Platform for Strategic Partnering

Partner with an end-to-end, off-the-shelf iPSC platform designed to scale across indications.

Learn more

Arrange a Meeting with Us